Неалкогольная Жировая Болезнь Печени У Лиц С Нормальным Весом: Современные Представления И Подходы (Обзор Литературы)

Stepanov, Yu.М.; Zavhorodnia, O.Yu.

doi:10.22141/2308-2097.54.3.2020.211738

GASTRO

2021

DOI: 10.22141/2308-2097.54.3.2020.211738

|View full text |Cite

Неалкогольная Жировая Болезнь Печени У Лиц С Нормальным Весом: Современные Представления И Подходы (Обзор Литературы)

Yu.М. Stepanov¹,

O.Yu. Zavhorodnia²

Abstract: Загальновживаний термін «худа НАЖХП» (lean NAFLD) або «НАЖХП без ожиріння» (nonobese NAFLD) є граматично і науково неточним, оскільки НАЖХП cама по собі не може бути «худою» або «без

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The Effectiveness of Complex Therapy With the Inclusion of the Ursodeoxycholic Acid in Patients With Non-Alcoholic Fatty Liver Disease in Combination With Chronic Obstructive Pulmonary Disease

et al. 2021

View full text Add to dashboard Cite

The aim: Was increase the effectiveness of treatment in patients with non-alcoholic fatty liver disease (NAFLD) comorbid with chronic obstructive pulmonary disease (COPD) by using ursodeoxycholic acid (UDCA) in combination with ademethionine. Materials and methods: Under observation was 98 patients with a diagnosis of NAFLD and COPD group II or their combination. Patients were divided into 3 groups: 1 (n = 36) – COPD + NASH – in addition to standard COPD therapy received UDCA 15 mg / kg / day – 6 months and ademethionine 1000 mg IV once a day for 10 days, followed by oral administration of 500 mg 2 times per day – 20 days, and group 2 (n = 32) – COPD + hepatic steatosis – in addition to standard therapy – UDCA 15 mg / kg / day – 6 months. Group 3 (n = 30) – COPD received standard therapy for COPD. Results: UDCA with ademethionine on the background of standard COPD therapy reduces the clinical manifestations of NAFLD and normalizes liver function. The combination of UDCA with ademethionine not only has a positive effect on the course of NAFLD, but also reduces the intensity of dyspnea, systemic inflammation, improves the external respiration function and reduces anxiety and depression. Patients receiving UDCA + ademethionine for 6 months of follow-up had no exacerbations of COPD. Conclusions: UDCA in combination with ademethionine in COPD courses have a positive effect on the course of NAFLD, and also reduces the intensity of dyspnea, improves the external respiratory function and reduces the frequency of COPD hospitalization.

show abstract

The Effectiveness of Complex Therapy With the Inclusion of the Ursodeoxycholic Acid in Patients With Non-Alcoholic Fatty Liver Disease in Combination With Chronic Obstructive Pulmonary Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Неалкогольная Жировая Болезнь Печени У Лиц С Нормальным Весом: Современные Представления И Подходы (Обзор Литературы)

Cited by 1 publication

References 34 publications

The Effectiveness of Complex Therapy With the Inclusion of the Ursodeoxycholic Acid in Patients With Non-Alcoholic Fatty Liver Disease in Combination With Chronic Obstructive Pulmonary Disease

The Effectiveness of Complex Therapy With the Inclusion of the Ursodeoxycholic Acid in Patients With Non-Alcoholic Fatty Liver Disease in Combination With Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About